The drug pricing debate in the United States has created plenty of smoke. Now for the fire.
The Centers for Medicare and Medicaid services (CMS) this week proposed a pilot pricing model to cut spending on expensive drugs. The rules apply to Medicare Part B, which covers infused or injected drugs administered to older Americans in doctors' offices and hospitals. It would reduce payments to doctors for more-expensive drugs while boosting reimbursements for cheaper options. The industry and some doctors are, unsurprisingly, unthrilled.
Read Full Article »